Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

NCT02311673 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Prader-Willi Syndrome

Interventions

DRUG: Setmelanotide
DRUG: Placebo

Sponsor

Rhythm Pharmaceuticals, Inc.